State of the Industry Webcast
Please join us for this free, live Ask the Expert webcast.
Just fill out the form below to register.
Partner, Latham Biopharm Group
Joshua Speidel, PhD, leads Government Services helping clients identify, win and execute on government grants and contracts. He formerly lead the development and execution Product Development Management, Strategic Consulting, and Medical Device/Diagnostic Development sector offerings at Latham Biopharm Group, providing subject matter expertise and advisory services on pharmaceutical product development, mergers and acquisition, strategic business development, and due diligence to clients. Dr. Speidel is a biotechnology product development professional with experience from pre-discovery through lifecycle management of mature products destined for the HHS Pandemic Influenza Vaccine Stockpile. Dr. Speidel provides technical expertise, program management and federal contract compliance support to clients. Speidel received a PhD in Physiology and Biophysics from Cornell University, a MSc in Biochemistry and Biophysics from the University of Houston and a BS in Biochemistry and Molecular Biology from Pennsylvania State University.
President & CEO, Lykan Biosciences
As President and CEO of Lykan, Patrick is responsible for driving dynamic growth of the company, developing infrastructure and efficiencies and ensuring successful execution and delivery to our clients.
Prior to joining Lykan, Patrick spent 19 years at Pfenex Inc., which began with the spin out of the novel protein production platform from The Dow Chemical Company into a stand-alone biotechnology company. Patrick played an instrumental role in the development of Pfenex’s initial strategy and evolving that strategy over time to derive greater value from the platform. Pfenex successfully completed an initial public offering in 2014 and received their first FDA product approval in 2019. Patrick and his team built the diverse Pfenex portfolio through licensing, development agreements and partnerships, which ultimately led to the acquisition of the company by Ligand Pharmaceuticals in 2020.
Previously, Patrick held various roles in business development, operations, QC, validation and capital project management at Repligen Corporation, Celltech Biologics, Lonza Biologics and Collaborative BioAlliance.
Head of Market Entry Strategy, Virus Based Therapeutics, Sartorius
Amélie Boulais has been working with Sartorius since 2008, where today she is the Head of Market Entry Strategy, Virus Based Therapeutics. She earned her Master’s Degree in Biotechology Engineering from the Biotechnology Engineering Institute ENSTBB of Bordeaux, France (ENSTBB). In her current role, Amélie determines the go-to-market strategy for the Viral-based Therapeutics segment, covering both vaccine and gene therapies. Her previous roles at Sartorius include Manager Vaccine Applications, Process Development Consultant, and Application Specialist for the Purification Technologies division.